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Veronica Gillispie, MD, Sandra Hurtado, MD, JinHee Kim, MD, Ran Liu, PhD, Charlotte D. Owens, MD,
Ozgul Muneyyirci-Delale, MD, Alice Wang, MA, Nelson B. Watts, MD, and William D. Schlaff, MD
OBJECTIVE: To investigate the safety and efficacy of
elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12
months in women with heavy menstrual bleeding associated with uterine leiomyomas.

METHODS: Elaris UF-EXTEND was a phase 3 extension
study that evaluated an additional 6 months (up to 12
months total) of elagolix 300 mg twice daily with
hormonal add-back therapy (estradiol 1 mg and norethindrone acetate 0.5 mg once daily) in women who
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completed an initial 6 months of the same treatment in
one of two preceding phase 3 studies. The primary
endpoint was the percentage of women with both less
than 80 mL menstrual blood loss during final month and
a 50% or greater reduction in menstrual blood loss from
baseline to final month. Safety evaluations included
adverse events and bone mineral density changes. The
planned sample size of UF-EXTEND was based on
estimated rollover and discontinuation rates in the two
preceding studies.
RESULTS: From September 2016 to March 2019, 433
women were enrolled in UF-EXTEND. Of these women,
218 received up to 12 months of elagolix with add-back
therapy; the mean6SD age of this group was 42.465.4
years and 67.3% were black. The percentage of women
who met the primary endpoint in this elagolix with addback group was 87.9% (95% CI [83.4–92.3]). The most
frequently reported adverse events with up to 12 months
of elagolix plus add-back therapy were hot flush (6.9%),
night sweats (3.2%), headache (5.5%), and nausea (4.1%).
Mean percent decreases in bone mineral density from
baseline to extension month 6 were significantly less with
elagolix plus add-back therapy than with elagolix alone
{between-group difference in lumbar spine: 23.3 (95%
CI [24.1 to 22.5])}.
CONCLUSION: Up to 12 months of elagolix with addback therapy provided sustained reduction in menstrual
blood loss in women with uterine leiomyomas, with the
addition of add-back therapy attenuating the hypoestrogenic effects of elagolix alone. No new or unexpected
safety concerns were associated with an additional 6
months of elagolix with addback therapy.
CLINICAL TRIAL
NCT02925494.

REGISTRATION: ClinicalTrials.gov,

FUNDING SOURCE: AbbVie Inc funded this study.
(Obstet Gynecol 2020;135:1313–26)
DOI: 10.1097/AOG.0000000000003869

U

terine leiomyomas are the most common noncancerous neoplasms of the uterus affecting up to
80% of reproductive-age women.1,2 They produce
a variety of symptoms in about half of these women,
the most common being heavy menstrual bleeding,
which can lead to anemia.3–5 Leiomyomas can have
a major effect on a woman’s quality of life.6–11 Surgery has been the mainstay of leiomyoma treatment,
with hysterectomy accounting for almost 70% of
leiomyoma-related procedures.12,13 Medical treatment, consisting of oral contraceptives, progestins,
tranexamic acid, and gonadotropin-releasing hormone agonists (ie, leuprolide acetate) are often used
to provide symptomatic relief; most of which are lim-
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ited to short-term efficacy.14–16 There is a clinical
unmet need for an approved long-term oral medical
treatment, as an alternative to surgery, that safely and
effectively manages heavy menstrual bleeding and improves leiomyoma-related symptoms and quality of
life for women with symptomatic leiomyomas.
Elagolix is an oral, nonpeptide gonadotropinreleasing hormone antagonist that results in dosedependent suppression of gonadotropins and ovarian
sex hormones and is approved for the management of
moderate-to-severe pain related to endometriosis.
Here we report results from a phase 3 extension
study (Elaris UF-EXTEND) that investigated the
efficacy of elagolix 300 mg twice daily with hormonal
add-back therapy (estradiol 1 mg and norethindrone
acetate 0.5 mg once daily) in reducing heavy menstrual bleeding in women with uterine leiomyomas for
up to 12 months of continuous treatment and the
longer-term effects of this treatment on hypoestrogenic side effects (bone mineral density decrease and
vasomotor symptoms).

ROLE OF THE FUNDING SOURCE
AbbVie Inc, funded this study and participated in the
study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the
publication. The authors had access to relevant
aggregated study data and other information (such
as study protocol, analytic plan and report, validated
data table, and clinical study report) required to
understand and report research findings. The authors
vouch for the presentation and publication of the
research findings, have been fully involved at all
stages of publication and presentation development,
and are willing to take public responsibility for all
aspects of the work. All individuals included as
authors and contributors who made substantial intellectual contributions to the research, data analysis,
and publication or presentation development are
listed appropriately. The role of the sponsor in the
design, execution, analysis, reporting, and funding is
fully disclosed. The authors’ personal interests, financial or nonfinancial, relating to this research and its
publication have been disclosed.

METHODS
Elaris UF-EXTEND was conducted at 115 sites in the
United States (including Puerto Rico) and Canada
from September 2016 to March 2019. This extension
study enrolled women who completed 6 months of
treatment in one of the two preceding, randomized,
double-blind, placebo-controlled, 6-month phase 3
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studies (Elaris UF-1 and UF-2). Women who received
elagolix 300 mg twice daily with add-back therapy
(estradiol 1 mg and norethindrone acetate 0.5 mg
once daily) or elagolix 300 mg twice daily alone in
UF-1 or UF-2 continued the same treatment for an
additional 6 months in the UF-EXTEND extension
study; women on placebo were randomized 1:1 to
receive either elagolix with add-back therapy or
elagolix alone for up to 6 months of treatment. All
women were followed up to 12 months posttreatment.
Study participants were provided with a known dose
of elagolix; however, the elagolix with add-back dose
was blinded. Study site personnel and participants
remained blinded to each participant’s original treatment from the preceding UF-1 and UF-2 trials and
throughout this extension study. This study was
approved by the institutional review board or ethics
committee for each study site and was conducted in
accordance with International Conference on Harmonisation guidelines and applicable regulations and ethical principles of the Declaration of Helsinki.
Here we report results from women who received
up to an additional 6 months (12 continuous months
total) of elagolix with add-back therapy or elagolix
alone in UF-EXTEND; the elagolix alone arm was
used to characterize the effect of add-back therapy on
hypoestrogenic effects of elagolix. Results from
women who received placebo in UF-1 or UF-2 and
up to 6 months of elagolix treatment in UF-EXTEND
are presented in Appendices 1–4, available online at
http://links.lww.com/AOG/B843.
As previously described, up to 6 months of
elagolix with add-back therapy achieved statistical
significance compared with placebo (P,.001) in
reducing menstrual blood loss in women with heavy
menstrual bleeding associated with uterine leiomyomas in both UF-1 and UF-2.17 In the present manuscript, data from UF-1 and UF-2 were pooled and
presented side-by-side with the UF-EXTEND data
to assess sustainability of elagolix effects across the
12-month treatment course.
Eligibility criteria for Elaris UF-1 and UF-2 have
been previously described.17 Briefly, participants
were premenopausal women between 18 and 51 years
of age who had an ultrasound-confirmed diagnosis of
uterine leiomyomas and heavy menstrual bleeding
(more than 80 mL of menstrual blood loss per cycle
as measured with alkaline hematin) at the time of
screening. Women who completed the 6-month treatment period in UF-1 or UF-2 were eligible to enter
UF-EXTEND if they had a bone mineral density
decrease less than 8% in the spine, total hip, and femoral neck, had no clinically significant endometrial

pathology on endometrial biopsy, and provided written, informed consent for extended treatment.
All women were instructed to use two forms of
nonhormonal contraception (ie, condom with spermicide, diaphragm with spermicide, cervical cap with
spermicide) consistently throughout UF-1 and -2 and
UF-EXTEND; pregnancy tests were performed
monthly at each study visit. In addition, women
who were anemic (hemoglobin of less than 12 g/dL)
at screening or during the studies were instructed to
take iron supplements (300–325 mg of ferrous sulfate); the regimen was determined by the investigator.
All bleeding endpoints were assessed using the
alkaline hematin method, which objectively quantifies
the amount of blood in used sanitary products collected
during the 6-month treatment period of UF-EXTEND
and up through the first menses with full menstrual
flow in the posttreatment follow-up period.17,18
Women who did not return any used sanitary products
at any visit during the treatment period or before the
first menses in the posttreatment follow-up period were
asked a standardized question to determine whether or
not they had any menstrual bleeding or spotting since
their previous study visit. If no bleeding was indicated
over an interval, the menstrual blood loss over the
interval was considered as zero.
As in UF-1 and UF-2, the primary efficacy
endpoint of UF-EXTEND was the percentage of
women who had less than 80 mL of menstrual blood
loss during the final month and a 50% or greater
reduction in menstrual blood loss from baseline to
final month. Women who met these two criteria of the
primary endpoint but prematurely discontinued study
drug because of an adverse event, lack of efficacy, or
required surgery or invasive intervention for treatment of uterine leiomyomas were categorized as not
having met the primary endpoint. A sensitivity
analysis of the primary endpoint was also performed
without taking into account reasons for premature
discontinuation of the study drug. Secondary efficacy
endpoints included change and percent change from
baseline in menstrual blood loss to each month and
final month, percentage of women with suppression of
bleeding (no bleeding, spotting allowed) at the final
month, and percentage of women with baseline
hemoglobin of 10.5 g/dL or less who had an increase
in hemoglobin greater than 2 g/dL at month 6. Other
efficacy endpoints included the percentage of women
with amenorrhea at final month and control of
bleeding (no bleeding, up to 1 day of spotting allowed)
at final month and change from baseline in the
Uterine Fibroid Symptom and Health-Related Quality of Life Questionnaire scores at month 6.17,19
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Average leiomyoma and uterine volume were
assessed during UF-EXTEND treatment and posttreatment follow-up periods by pelvic ultrasonography (transabdominal and transvaginal) in all women
and by magnetic resonance imaging (MRI) in a subset
of women who elected to participate in additional
imaging. Average leiomyoma volume was measured
based on the average of up to three leiomyomas
observed at the given time point. All imaging assessments were read centrally (Parexel International
Corporation, Waltham, Massachusetts).
Adverse events were coded using the Medical
Dictionary for Regulatory Activities 21.0 and categorized by severity (mild, moderate, or severe) by
investigators. Adverse events with new onset (or
changed severity) on or after the first dose date and
within 30 days after the last dose date were considered
treatment-emergent. Serious adverse events were
those that were life-threatening, required hospitalization or prolongation of hospitalization, required
medical or surgical intervention to prevent serious
outcome, or resulted in persistent or significant
disability or death. Hot flushes and night sweats were
also self-reported at scheduled visits by women in
a supplemental questionnaire; women who reported
an adverse event of hot flush or night sweats were
asked the number and severity of either or both hot
flushes and night sweats they experienced over the
previous 24 hours at each visit thereafter until
resolution of the adverse event.
Bone mineral density in the lumbar spine, total
hip, and femoral neck were assessed by dual-energy
X-ray absorptiometry scans (GE-Lunar, Madison,
Wisconsin; Hologic, Marlborough, Massachusetts),
which were performed every 6 months during the
treatment and posttreatment follow-up periods of this
extension study, and were read centrally (Parexel
International Corporation, Waltham, Massachusetts).
Clinical laboratory tests, including hemoglobin, lipid
panel, and liver function tests, were performed during
the screening period of the preceding UF-1 and UF-2
studies, at baseline and each treatment month (or at
premature discontinuation), and at applicable posttreatment follow-up visits, and were read centrally
(Q2 Solutions, Valencia, California). Endometrial
biopsies were performed during screening and at
month 6 (or at premature discontinuation) and read
centrally (Q2 Solutions).
Approximately 400 women were expected to
enroll in the Elaris UF-EXTEND study based on
estimated rollover and discontinuation rates in Elaris
UF-1 and UF-2. All efficacy and safety analyses
included all women who received at least one dose
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of the study drug in this extension study, including
those who prematurely discontinued the study drug or
withdrew consent. Baseline values for all measures
were defined as before dosing in either UF-1 and UF-2
for women who received elagolix treatment in those
studies (for women who received placebo in UF-1 or
UF-2, baseline was defined as the last value before the
first dose of elagolix in UF-EXTEND, unless otherwise specified). Final month was defined as the last 28
days before and including the last dose date in UFEXTEND.
Statistical comparisons between the elagolix with
add-back therapy and elagolix-alone groups that
received up to 12 months of treatment were not
prespecified and therefore were not performed in UFEXTEND, as the study was not designed for these
analyses, except when evaluating changes in
bone mineral density. The primary endpoint and
secondary endpoints of categorical assessments (eg,
percentage of women with suppression of bleeding at
the final month and percentage of women with
baseline hemoglobin of 10.5 g/dL or less who had
an increase in hemoglobin greater than 2 g/dL at
month 6) were summarized by frequency and percentages. The secondary endpoints of all change and
percent change from baseline analyses were summarized with descriptive statistics. Statistical testing was
only performed for percent changes in bone mineral
density using SAS 9.4 with an analysis of covariance
model with treatment as the main effect and baseline
value as a covariate with a two-sided significance level
of 0.05 and a 95% CI.

RESULTS
A total of 433 women who completed the 6-month
treatment period in Elaris UF-1 or UF-2 were enrolled
and treated in Elaris UF-EXTEND (Fig. 1). Of these
women, 218 were treated with elagolix plus add-back
therapy (98 with elagolix alone) in the preceding studies and continued the same treatment for up to an
additional 6 months in UF-EXTEND; thus, were
included in this analysis. Similar proportions of
women in each treatment group (16.5% for elagolix
with add-back therapy and 19.4% for elagolix alone)
discontinued the study drug, with the most common
primary reason for discontinuation being lost to
follow-up (5.0% and 5.1% respectively). As summarized in Table 1, the demographics and baseline characteristics of women enrolled in UF-EXTEND were
generally well-balanced across the treatment groups
and similar to those of the overall population of UF1 and UF-2.

Twelve Months of Elagolix With Add-Back Therapy
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Fig. 1. Study design and disposition of women treated with up to 12 months of elagolix. Elagolix alone, elagolix 300 mg
twice daily throughout UF-1 and UF-2 and UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with
add-back therapy (estradiol 1 mg and norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. *In
UF-1 and UF-2 combined, 5 of 150 (3.3%) women treated with elagolix alone and 3 of 312 (1.0%) women treated with
elagolix plus add-back therapy did not enter UF-EXTEND because of a dual-energy X-ray absorptiometry scan (DXA) finding
of bone mineral density decrease greater than 8% in at least one of the anatomic locations (lumbar spine, total hip, and
femoral neck). †The most common other reason was that the extension study was closed to enrollment. ‡Women required
surgery or invasive intervention for treatment of uterine leiomyomas. Other reasons for premature discontinuation included
moved out of state (n52), weight exceeded DXA limits, study site closing, participant stopped drug because she thought she
was pregnant but was not, did not like bleeding while on medication, personal reasons, and DXA results.
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.
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Table 1. Patient Demographics and Baseline Characteristics in Women Treated With Up to 12 Months of
Elagolix*

Age (y)
Race
White
Black or African American
Other
Missing
BMI (kg/m2)
MBL (mL)
Hemoglobin (g/dL)
Uterine volume (cm3)
TAU, TVU
MRI
Average leiomyoma volume (cm3)
TAU/TVU
MRI
UFS-QOL score
Symptom severity
Total HRQOL
BMD Z-score
Lumbar spine
Total hip
Femoral neck

Elagolix Alone (n598)

Elagolix With Add-Back Therapy (n5218)

42.265.4

42.465.4

25 (25.8)
70 (72.2)
2 (2.0)
1
35.467.5
260.96181.5
10.861.6

65 (30.0)
146 (67.3)
6 (2.8)
1
33.766.8 (n5217)
224.76147.9
11.161.5

594.46589.3
830.56980.9 (n552)

485.16381.2
590.56441.5 (n5110)

68.76137.5 (n597)
91.26127.3 (n549)

54.5672.5 (n5213)
73.6664.3 (n599)

63.6620.9 (n597)
41.5624.2 (n597)

58.4621.6 (n5217)
44.4624.0 (n5217)

1.061.1
0.961.0
0.760.9

1.161.1
0.860.9
0.760.9

BMI, body mass index; MBL, menstrual blood loss; TAU, transabdominal ultrasonography; TVU, transvaginal ultrasonography; MRI,
magnetic resonance imaging; UFS-QOL, Uterine Fibroid Symptom and Quality of Life Questionnaire; HRQOL, health-related quality of
life; BMD, bone mineral density.
Data are mean6SD or n (%).
Demographics and baseline characteristics for all women are from before first dosing in Elaris UF-1 or UF-2. For uterine volume, average
leiomyoma volume, and UFS-QoL scores, if no measurement was collected on or before day 1 in UF-1 or -2, the first measurement
collected before day 8 in UF-1 or -2 was used as baseline.
*Elagolix alone5elagolix 300 mg twice daily throughout UF-1 and -2 and UF-EXTEND; elagolix with add-back therapy5elagolix 300 mg
twice daily with add-back (estradiol 1 mg and norethindrone 0.5 mg once daily) throughout UF-1 and -2 and UF-EXTEND.

Of the women who received up to 12 months of
elagolix with add-back therapy in Elaris UFEXTEND, the proportion who met the two bleeding

criteria of the primary endpoint was 87.9% (95% CI
[83.4–92.3], n5206) and 89.4% (95% CI [83.1–95.6],
n594) for elagolix alone; Appendix 5, available

Fig. 2. Percentage of women who met the primary endpoint (A) and mean change from baseline in menstrual blood loss in
women treated with up to 12 months of elagolix with add-back therapy (B). Data are % or mean with error bars indicating
95% CI. Baseline was before first dosing in the UF-1 and UF-2 studies. *Mean changes from baseline in menstrual blood loss
for UF-1 and UF-2 are presented as least squares means.
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.
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online at http://links.lww.com/AOG/B843); these results were consistent with the results pooled from UF1 and UF-2 {72.2% (95% CI [67.7–76.7]) for elagolix
with add-back therapy and 80.6% (95% CI [74.9–86.
2]) for elagolix alone} (Fig. 2A; Appendix 5 [http://
links.lww.com/AOG/B843]). The results of a sensitivity analysis of the primary endpoint which did not
consider reasons for premature discontinuation of
the study drug were similar to those of the primary
analysis (Appendix 6, available online at http://links.
lww.com/AOG/B843). Results of the primary endpoint from women who received placebo in either
UF-1 or UF-2 and up to 6 months of elagolix treatment in UF-EXTEND are presented in Appendix 3
(http://links.lww.com/AOG/B843).
Mean reductions in menstrual blood loss seen at
month 6 of UF-1 and UF-2 were sustained through an
additional 6 months of elagolix with add-back therapy
during UF-EXTEND; mean changes from baseline
ranged from 2186.5 mL (95% CI [2209.2 to 2163.9])
at extension month 1 to 2211.4 mL (95% CI [2239.1
to 2183.7]) at extension month 6 (Fig. 2B; mean percent change in Appendix 7, available online at http://
links.lww.com/AOG/B843). The majority of women
receiving elagolix with add-back therapy achieved
suppression of bleeding {74.8% (95% CI [68.8–80.
7])} at the final month of UF-EXTEND; the corresponding percentage at the final month of UF-1 and
UF-2 combined was 58.9% (95% CI [53.8–64.0])
(Table 2). Additionally, the majority of women receiving elagolix with add-back therapy who had a low
baseline hemoglobin level of 10.5 g/dL or less showed

an increase from baseline greater than 2 g/dL at UFEXTEND month 6 (72.5%, 95% CI [60.3–84.8]); the
corresponding percentage at month 6 of UF-1 and
UF-2 combined was 56.0% (95% CI [46.3–65.7])
(Table 2). Results of secondary and other efficacy endpoints from women who received elagolix alone up to
12 months are presented in Appendix 5 (http://links.
lww.com/AOG/B843) and in Appendix 3 (http://
links.lww.com/AOG/B843) for women who received
placebo in UF-1 or UF-2 and up to 6 months of elagolix treatment in UF-EXTEND.
More than half of the women who received up to
12 months of elagolix with add-back therapy achieved
amenorrhea (64.6%, 95% CI [58.0–71.1]) and control
of bleeding (64.6%, 95% CI [58.0–71.1]) at the final
month of UF-EXTEND, respectively. In the elagolix
with add-back group, there was a small increase in
mean average leiomyoma volume from baseline to
UF-EXTEND month 6 (1.5 cm3 [95% CI 26.0 to
8.9] measured by ultrasound scan and 9.4 cm3 [95%
CI 21.2 to 20.0] by MRI); however, mean uterine
volume was reduced at UF-EXTEND month 6
{257.3 cm3 (95% CI [285.0 to 229.5]) by ultrasound
scan and 230.0 cm3 (95% CI [265.8 to 5.8]) by MRI}
(Appendix 8, available online at http://links.lww.
com/AOG/B843). Elagolix with add-back treatment
was also associated with improved quality of life based
on mean changes from baseline to UF-EXTEND
month 6 in Uterine Fibroid Symptom and HealthRelated Quality of Life Questionnaire scores, including symptom severity score and total HRQL score
(subscales included Concern, Activities, Energy and

Table 2. Secondary and Other Efficacy Endpoints After 6 Months and 12 Months of Elagolix Treatment in
Women Treated With Up to 12 months of Elagolix*
Endpoint (Timepoint)

Elagolix With Add-Back Therapy

Women with amenorrhea
UF-1 and -2 final month
UF-EXTEND final month
Women with control of bleeding
UF-1 and -2 final month
UF-EXTEND final month
Women with suppression of bleeding
UF-1 and -2 final month
UF-EXTEND final month
Women with baseline hemoglobin of 10.5 g/dL or less who had an increase of more than
2 g/dL†
UF-1 and -2 month 6
UF-EXTEND month 6

50.4 (45.2–55.6)
64.6 (58.0–71.1)
50.4 (45.2–55.6)
64.6 (58.0–71.1)
58.9 (53.8–64.0)
74.8 (68.8–80.7)

56.0 (46.3–65.7)
72.5 (60.3–84.8)

Data are % (95% CI).
*Elagolix with add-back therapy5elagolix 300 mg twice daily with add-back (estradiol 1 mg and norethindrone 0.5 mg once daily)
throughout UF-1 and -2 and UF-EXTEND.
†
Baseline was before first dosing in UF-1 and UF-2 studies.
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mood, Control, Self-conscious, Sexual function)
(Appendix 9, available online at http://links.lww.
com/AOG/B843).
Furthermore, of the women who received up to
an additional 6 months of elagolix with add-back
therapy during UF-EXTEND and entered the posttreatment follow-up period (n5184), the majority of
these women (79.3%) reported a first posttreatment
menses within 2 months after stopping the study drug;
mean volume of the first posttreatment menses was
198.7 mL.
Approximately 60% of women who received up
to 12 months of elagolix with add-back therapy or
elagolix alone had at least one treatment-emergent
adverse event with an onset on or after the first dose of
study drug in this extension study (Table 3). The most
frequently reported adverse events with elagolix plus
add-back therapy were hot flush and headache; which
are consistent with those of UF-1 and UF-2. The most
common adverse events leading to treatment discontinuation during the second 6 months of treatment
were bone density decrease (elagolix alone: four
[4.1%]; elagolix with add-back therapy: one [0.5%])
and depression (elagolix alone: one [1.0%]; elagolix
with add-back therapy: one [0.5%]). The majority of
adverse events were considered nonserious and mild
or moderate in severity by investigators. Serious
adverse events that led to study drug discontinuation
included breast cancer (n51), menorrhagia and pelvic
pain (n51), and hysterectomy (n51); all of which
occurred in the elagolix with add-back group. The
profile of adverse events from women who received
placebo in UF-1 or UF-2 and up to 6 months of elagolix treatment in UF-EXTEND are presented in
Appendix 4 (http://links.lww.com/AOG/B843). The

rate of adverse events over the course of 12 months of
elagolix treatment are listed in Appendix 10, available
online at http://links.lww.com/AOG/B843.
There was one pregnancy that was reported
during the treatment period of UF-EXTEND;
a woman had a positive urine pregnancy test confirmed by a positive serum pregnancy test on day 90,
discontinued the study drug the same day, and had
a spontaneous abortion on day 95 (Posttreatment day
6). No deaths were reported in the elagolix treatment
groups during the extension study.
Among women who received up to 12 months of
elagolix treatment, the overall rate of either or both
hot flushes and night sweats with new onset in this
extension study were reported by 7.8% of women in
the elagolix with add-back group and 5.1% in the
elagolix-alone group; none of these women discontinued the study drug because of either or both hot
flush and night sweat events, as none of the events
were considered serious by investigators. Based on
a supplemental form completed by the women
themselves, fewer women in the elagolix with addback group (range, n 5 19–29) reported either or both
hot flush and night sweats every month during the
treatment period even though the elagolix with addback group had approximately twice as many women
as the elagolix-alone group (range, n 537–49,
Appendix 11, available online at http://links.lww.
com/AOG/B843). Participant-reported supplemental
form data also showed that a smaller percentage of
women in the elagolix with add-back group than in
the elagolix-alone group had a maximal severity of
moderate or severe for either or both hot flush and
night sweat events at most treatment months. The
mean number of these events were lower in the

Table 3. Overview of Treatment-Emergent Adverse Events During UF-EXTEND for Women Who Received
Up to 12 Months of Elagolix*
Elagolix Alone
(n598)

Adverse Event
Any
Any serious
Any severe
Any leading to study drug discontinuation
Any fatal
Occurred in 5% or more of participants across elagolix treatment
groups
Hot flush
Headache

60
2
3
7

(61)
(2)
(3)
(7)
0

3 (3)
4 (4)

Elagolix With Add-Back Therapy
(n5218)
134 (61)
6 (3)
14 (6)
8 (4)
0

15 (7)
12 (6)

Data are n (%).
Adverse events are listed by patient incidence in descending order by elagolix with add-back therapy. Only treatment-emergent adverse
events that occurred (or changed severity) during UF-EXTEND are presented here.
* Elagolix alone5elagolix 300 mg twice daily throughout UF-1 and -2 and UF-EXTEND; elagolix with add-back therapy5elagolix 300 mg
twice daily with add-back (estradiol 1 mg and norethindrone 0.5 mg once daily) throughout UF-1 and -2 and UF-EXTEND.
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elagolix with add-back group than in the elagolixalone group at most months (Appendix 12, available
online at http://links.lww.com/AOG/B843).
The lumbar spine mean bone mineral density
percent change from baseline for the elagolix alone
treatment group was 24.8% (95% CI [25.4 to 24.1];
median Z-score 0.5) and for elagolix with add-back
therapy 21.5% (95% CI [21.9 to 21.0]; median Zscore 0.8) in women who received up to 12 months of
treatment at UF-EXTEND month 6 (Fig. 3). At the
same anatomical location, at posttreatment month 6
the mean bone mineral density percent change from
baseline for the elagolix alone treatment group was
22.8% (95% CI [23.6 to 21.9]; median Z-score 0.5)
and for elagolix with add-back therapy 20.6% (95%
CI [21.1 to 20.1]; median Z-score 1.0), and at posttreatment Month 12, 22.0% (95% CI [22.8 to 21.2];
median Z-score 0.6), and 20.6% (95% CI [21.1 to
20.0]; median Z-score 1.1), respectively. Similar
trends were seen at the total hip and femoral neck
locations (Figs. 4 and 5).
Bone mineral density changes from baseline were
less with elagolix with add-back therapy compared
with elagolix alone; the differences between groups
were statistically significant. For all locations, a higher
percentage of women in the elagolix with add-back
group than in the elagolix-alone group had an
increase or no change in bone mineral density from
baseline to UF-EXTEND month 6. A smaller percentage of women in the elagolix with add-back group
than in the elagolix-alone group had more than 3%
bone mineral density decreases at UF-EXTEND
month 6 (Appendix 13, available online at http://
links.lww.com/AOG/B843). Thirty women treated
with elagolix for up to 12 months (23 in the
elagolix-alone group and seven in the elagolix with
add-back group) had an 8% or greater bone mineral
density decrease at one or more anatomic locations
during the 6 months of UF-EXTEND, of whom five
(four in the elagolix-alone group and one in the elagolix with add-back group) had a Z-score of 21.5 or
less in the same location where they had the 8% or
greater bone mineral density decrease. None of these
30 women had bone fractures. At UF-EXTEND posttreatment months 6 and 12 for all anatomical locations, no women at any anatomical location had a Zscore less than 22.0, the lower bound of the normal
age- and race-matched range (Figs. 3–5).20
Women who received up to 12 months of elagolix
treatment had transient elevations in low-density
lipoprotein cholesterol (LDL-C) and apolipoprotein
B that generally occurred within the first 3 months of
treatment during UF-1 and UF-2 and then stabilized.

The mean increases in these serum lipid levels were
lower with elagolix plus add-back therapy than with
elagolix alone (Appendix 14, available online at
http://links.lww.com/AOG/B843). In the elagolix
with add-back group, both mean LDL-C and apolipoprotein B levels returned to near baseline levels by
posttreatment follow-up month 3. Mean triglyceride
levels were generally similar to baseline in the elagolix
with add-back group and were lower than in the
elagolix-alone group.
None of the women discontinued the study drug
because of an adverse event of anemia. In women
receiving up to 12 months of elagolix, treatment led to
increases in mean hemoglobin levels from baseline
(Appendix 15, available online at http://links.lww.
com/AOG/B843).
Two women who received up to 12 months of
elagolix treatment (one in the elagolix with add-back
group and one in the elagolix-alone group) had
elevations in liver transaminase levels during UFEXTEND that were more than three times or more
than five times the upper limit normal; neither had
concurrent elevations in bilirubin and no pattern in
time to onset was identified. In both of these women,
their elevations were asymptomatic and declined
within 1–4 months after peak values, regardless of
study drug continuation. Of these two women, only
the one in the elagolix-alone group discontinued the
study drug because of liver transaminase elevations;
her levels returned to normal after the study drug was
discontinued. Further, there were no cases of severe
liver injury (ie, irreversible liver failure that is fatal or
requires liver transplantation) reported in UFEXTEND, and no one met the biochemical criteria
for Hy’s law.
Results from the endometrial biopsy showed no
evidence of hyperplasia or malignancy at baseline or
UF-EXTEND month 6 and no treatment-emergent
adverse event of ovarian cysts were reported during
the extension study. Despite cycle-related differences,
mean endometrial thickness, as measured by ultrasound
scan or MRI, decreased from baseline to UF-EXTEND
month 6 in each of the two elagolix groups that received
up to 12 months of treatment (Appendix 16, available
online at http://links.lww.com/AOG/B843).
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DISCUSSION
Previous reports of two phase 3 studies (Elaris UF-1
and UF-2) showed that up to 6 months of elagolix 300
mg twice daily with hormonal add-back therapy (1 mg
estradiol and 0.5 mg norethindrone acetate once
daily), when compared with placebo, significantly
reduced menstrual bleeding and improved quality of
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Fig. 3. Lumbar spine bone mineral density changes from baseline (A) and bone mineral density Z-scores during treatment
and posttreatment periods in women treated with up to 12 months of elagolix (B). Bone mineral density changes are
presented as least square mean percent change, with error bars indicating 95% CI. Bone mineral density Z-scores are
presented as median, quartile 1, quartile 3, and range. Bone mineral density changes and Z-scores for UF-1 and UF-2
exclude participants who switched machine types. Elagolix alone, elagolix 300 mg twice daily throughout UF-1 and UF-2
and UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg and
norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. Baseline was before first dosing in UF-1 and
UF-2 studies. *P#.05 for test of difference between the elagolix with add-back therapy and elagolix-alone groups using an
analysis of covariance model with treatment as the main effect and baseline value as a covariate for extension month 6.
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.

life in women with heavy menstrual bleeding associated with uterine leiomyomas. Herein, this corresponding extension study demonstrated maintenance
of these effects for an additional 6 months (up to 12
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months total) of elagolix with add-back treatment. In
women who received up to 12 months of elagolix with
add-back therapy, the majority of women (87.9%) met
the primary endpoint of having both less than 80 mL
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Fig. 4. Total hip bone mineral density changes from baseline (A) and bone mineral density Z-scores during treatment and
posttreatment periods in women treated with up to 12 months of elagolix (B). Bone mineral density changes are presented as
least square mean percent change with error bars indicating 95% CI. Bone mineral density Z-scores are presented as
median, quartile 1, quartile 3, and range. Bone mineral density changes and Z-scores for UF-1 and UF-2 exclude
participants who switched machine types. Elagolix alone, elagolix 300 mg twice daily throughout UF-1 and UF-2 and
UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg
and norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. Baseline was before first dosing in UF-1
and UF-2 studies. *P#.05 for test of difference between the elagolix with add-back therapy and elagolix-alone groups using
an analysis of covariance model with treatment as the main effect and baseline value as a covariate for extension month 6.
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.

of menstrual blood loss at the final month and a 50%
or greater reduction in menstrual blood loss from
baseline to final month. Reductions in menstrual
blood loss were consistent across the 12-month

treatment course. Similar to the results of the preceding UF-1 and UF-2 studies, most women treated
with elagolix with add-back therapy achieved suppression of bleeding (74.8%) at the final month in
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Fig. 5. Femoral neck bone mineral density changes from baseline (A) and bone mineral density Z-scores during treatment
and posttreatment periods in women treated with up to 12 months of elagolix (B). Bone mineral density changes are
presented as least square mean percent change, with error bars indicating 95% CI. Bone mineral density Z-scores are
presented as median, quartile 1, quartile 3, and range. Bone mineral density changes and Z-scores for UF-1 and UF-2
exclude participants who switched machine types. Elagolix alone, elagolix 300 mg twice daily throughout UF-1 and UF-2
and UF-EXTEND; elagolix with add-back therapy, elagolix 300 mg twice daily with add-back therapy (estradiol 1 mg and
norethindrone 0.5 mg once daily) throughout UF-1 and UF-2 and UF-EXTEND. Baseline was before first dosing in UF-1 and
UF-2 studies. *P#.05 for test of difference between the elagolix with add-back therapy and elagolix-alone groups using an
analysis of covariance model with treatment as the main effect and baseline value as a covariate for extension month 6.
Simon. Twelve Months of Elagolix With Add-Back Therapy. Obstet Gynecol 2020.

UF-EXTEND and, among those with baseline hemoglobin of 10.5 g/dL or less, had an increase of more
than 2 g/dL in hemoglobin after 12 months of
treatment (72.5%).
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Safety findings in Elaris UF-EXTEND were also
consistent with those previously reported in the preceding 6 months UF-1 and UF-2 studies; the inclusion
of add-back therapy attenuated hypoestrogenic side
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effects associated with the use of elagolix alone,
including
hot
flushes,
night
sweats,
and
bone mineral density decreases. There were minimal
new cases of either or both hot flushes and night
sweats in UF-EXTEND. As expected, elagolix with
add-back therapy was associated with numerically
lower incidence and reduced severity of either or both
hot flushes and night sweats throughout the treatment
period based on patient-reported supplemental form
data.
The effect of add-back therapy on attenuating
bone mineral density changes, as seen with the initial
6 months of treatment in UF-1 and UF-2, were
maintained with up to an additional 6 months of
treatment
in
UF-EXTEND,
mean
percent
bone mineral density changes were statistically significantly less with elagolix plus add-back therapy than
with elagolix alone. Furthermore, a greater proportion
of women in the elagolix with add-back group than in
the elagolix-alone group had a numerical increase or
no change in bone mineral density. For women who
had a numerical decrease in bone mineral density
with up to 12 months of elagolix plus add-back
therapy, most were in a category of less than 5% for
lumbar spine.
Elagolix with add-back therapy was associated
with transient lipid elevations in LDL-C and apolipoprotein B that were first observed during the first 3
months of treatment in UF-1 and UF-2 and then
remained stable; an additional 6 months of treatment
in UF-EXTEND did not further increase the lipid
levels. The mechanism for these changes is not
known, but in most cases increases in concentrations
of apoB-containing lipoproteins are explained by
a reduction in LDL receptor-mediated clearance often
related to decreased receptor expression or function.21,22 After study drug discontinuation, lipid levels
usually returned to pretreatment levels by month 3 of
the posttreatment follow-up period.
There were some methodologic limitations inherent to UF-EXTEND. For example, women were
required to complete one of the preceding UF-1 or
UF-2 phase 3 studies to enroll in this extension study,
resulting in a potential selection bias for women who
responded to treatment. The absence of a placebo
control in UF-EXTEND also limits the interpretation
of the results. Despite these factors, the treatment
length is a strength of the extension study, as the
safety (including bone mineral density and other
hypoestrogenic effects) and efficacy of elagolix with
add-back therapy were evaluated for up to 12 months
of treatment, and bone mineral density recovery for
up to 12 months posttreatment. An additional strength

is the inclusion of the elagolix alone reference arm,
which was used to characterize the effects of add-back
therapy on the hypoestrogenic effects of elagolix. The
objective measurement of menstrual blood loss using
the alkaline hematin method also adds credibility to
the study as other methods, such as the pictorial blood
loss assessment chart and bleeding journals, are
semiquantitative and subjective.23–25
In conclusion, the results of UF-EXTEND demonstrated that up to 12 months of elagolix with addback therapy provided sustained efficacy in reducing
menstrual blood loss with no new or unexpected
adverse effects compared with results of the preceding
6-month UF-1 and UF-2 studies. Add-back therapy
continued to attenuate hypoestrogenic effects associated with the use of elagolix alone, which were
consistent across the 12-month treatment course.
These data support the evaluation of elagolix with
add-back therapy as a potential new, long-term, oral
treatment option for women with heavy menstrual
bleeding associated with uterine leiomyomas.
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